All In Biotech

NDA 022012 · Waylis Therap

Coreg Cr

Carvedilol Phosphate · Oral

Last checked: Nov 19, 2026Latest source record: Jul 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 20, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

238

43 Phase 3, 25 recruiting

FAERS reports

2,975

1,127 serious, 148 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 25, 2025.

COREG CR is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure. ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients. ( 1.2 ) hypertension. ( 1.3 ) 1.1 Heart Failure COREG CR is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG CR is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ] . 1.3 Hypertension COREG CR is ındicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ] .

Mechanism: Carvedilol is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2008 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form
  • Oct 20, 2006 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LabelReviewLetter
4 products under this application
  • COREG CR · CARVEDILOL PHOSPHATE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • COREG CR · CARVEDILOL PHOSPHATE 20MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • COREG CR · CARVEDILOL PHOSPHATE 40MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • COREG CR · CARVEDILOL PHOSPHATE 10MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carvedilol" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness309
  • fatigue298
  • drug ineffective291
  • dyspnoea192
  • nausea145
  • headache142
  • blood pressure increased139
  • diarrhoea131
  • hypotension121
  • asthenia109
  • malaise104
  • fall92

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2007499
2008443
2009305
2010155
2011162
2012126
2013145
2014210
2015196
2016162
2017124
2018100
2019112
202067
202134
202232
202319
202430
202534
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Coreg Cr (Carvedilol Phosphate)

2024 spending

$8.7M

Beneficiaries

1,081

4,102 claims

Per beneficiary

$8,057

$32.05 per unit

View as table
YearSpending
2020$4,294,026
2021$10,430,737
2022$6,236,938
2023$9,519,887
2024$8,709,775

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 803 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.